MG
INFI

Meditor Group’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Meditor Group’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-250,000
Closed -$4.05M – 42
2013
Q2 		$4.05M Buy
+250,000
New +$7.74M 0.55% 28

Other funds holding INFI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Meditor Group's INFI Position: Q3 2013 in Review

Meditor Group sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2013, closing a stake of 250,000 shares — an estimated $4.05M sold.

Meditor Group first reported a position in INFI in Q2 2013 and held it in 1 quarter. The position peaked at $4.05M in Q2 2013. 100 funds tracked by Wall St. Rank hold INFI as of Q3 2013.

  • Meditor Group reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Meditor Group sold 250,000 Infinity Pharmaceuticals, Inc. shares in Q3 2013, an estimated $4.05M.
  • Meditor Group first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Meditor Group's Infinity Pharmaceuticals, Inc. position peaked at $4.05M in Q2 2013.
  • 100 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2013.

Based on Meditor Group's 13F filing for Q3 2013, filed 25 Oct 2013.